The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Slides:

Advertisements

Similar presentations

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.

Advertisements

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

Treatment of early-stage Hodgkin lymphoma

Volume 155, Issue 3, Pages (March 1996)

Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma CCO Independent Conference Highlights of the 2015 ASCO Annual.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

by James O. Armitage, and Dan L. Longo

Hepatitis C in the rituximab era

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era Sarah F. Keller,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma by Alexandra Albertsson-Lindblad, Arne Kolstad,

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Protease inhibitors potentiate chemotherapy-induced neutropenia

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

How I treat refractory CLL

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma by Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg,

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Overall survival by SCT versus observation in first complete remission

Gordon L. Phillips, Steven H. Bernstein, Jane L. Liesveld, Camille N

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by Wendy Lim, Sara K. Vesely, and James N. George

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma per health-insurance (NHIF) status at diagnosis (P=0.003). Kaplan-Meier.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

Impact of age on clinical risk scores in follicular lymphoma

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Kaplan-Meier plots of the duration of continuous albuterol, time until q4 albuterol, and hospital LOS for each of the 4 treatment groups. Kaplan-Meier.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

How I treat early-relapsing follicular lymphoma

by Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

by Lapo Alinari, and Kristie A. Blum

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Optimizing therapy for nodal marginal zone lymphoma

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Outcomes in patients with PTCL

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick Peterson, Lynn Rich, Susan Blumel, Nicole K. Proia, Jane Liesveld, Richard I. Fisher, James O. Armitage, Steven Grant, and John P. Leonard Blood Volume 117(10):2807-2812 March 10, 2011 ©2011 by American Society of Hematology

Waterfall plot of best response after therapy. Waterfall plot of best response after therapy. Three of the treated patients (n = 30) are not included because of rapid clinical progression without additional imaging (n = 2) and 1 death before restaging evaluation. Jonathan W. Friedberg et al. Blood 2011;117:2807-2812 ©2011 by American Society of Hematology

Progression-free survival. Progression-free survival. Kaplan-Meier estimate progression-free survival, with number at risk, for (A) all treated patients (n = 30), (B) patients with follicular lymphoma (n = 15), and (C) patients with mantle cell lymphoma (n = 7). Jonathan W. Friedberg et al. Blood 2011;117:2807-2812 ©2011 by American Society of Hematology